1. Home
  2. INBS vs DRMA Comparison

INBS vs DRMA Comparison

Compare INBS & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intelligent Bio Solutions Inc.

INBS

Intelligent Bio Solutions Inc.

N/A

Current Price

$1.55

Market Cap

6.5M

Sector

Health Care

ML Signal

N/A

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

N/A

Current Price

$0.58

Market Cap

5.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INBS
DRMA
Founded
2016
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
5.6M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
INBS
DRMA
Price
$1.55
$0.58
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
36.1K
★ 95.3K
Earning Date
11-10-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $1,980,484.00
N/A
Revenue This Year
$44.72
N/A
Revenue Next Year
$44.26
$650.00
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.57
52 Week High
$24.90
$4.66

Technical Indicators

Market Signals
Indicator
INBS
DRMA
Relative Strength Index (RSI) 41.55 30.22
Support Level $1.44 N/A
Resistance Level $1.86 $1.40
Average True Range (ATR) 0.18 0.09
MACD -0.04 -0.01
Stochastic Oscillator 5.88 0.69

Price Performance

Historical Comparison
INBS
DRMA

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its current active product is the Intelligent Fingerprinting Platform, consisting of a proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its flagship product, the Intelligent Fingerprinting Drug Screening System, is a two-part system of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Company operates in APAC, the UK, the Americas, and the rest of the world, with maximum revenue from the United Kingdom.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: